Periodontal disease treatment system

• US 4,919,939 A
• Filed: 07/08/1988
• Issued: 04/24/1990
• Est. Priority Date: 04/29/1986
• Status: Expired due to Fees

• Current Assignee: Technical Chemicals And Products, Inc.
• Original Assignee: Pharmetrix Corporation
• Inventors: Baker, Richard W.
• Primary Examiner(s): NOT, DEFINED
• Application Number:
  US07/216,802
• Time in Patent Office: 655 Days
• Field of Search: 424/493, 424/489, 424/484, 424/490, 424/486, 424/497
• US Class Current: 424/493
• CPC Class Codes: A61K 6/30 Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives
• CPC Class Codes: A61K 6/69 Medicaments
• CPC Class Codes: A61K 9/0063 Periodont
• CPC Class Codes: A61K 9/1641 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: C08L 1/286 substituted with acid radicals, e.g. carboxymethyl cellulose [CMC] C08L1/282 takes precedence
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

A controlled release drug delivery system for placement in the periodontal pocket, gingival sulcus, tooth socket, wound or other cavity within the mouth. The system incorporates drug-containing microparticles in a fluid carrier medium, and is effective in the environment of use for up to 30 days.

Claims

1. A controlled drug delivery system for placement in a periodontal pocket, comprising:

(a) a plurality of discrete microparticles, between 10 and 500 microns in diameter, comprising a drug and a polymer containing said drug, wherein when said microparticles are placed in an environment of use, said drug is released at a controlled rate by a combination of diffusion of said drug through said polymer and erosion of said polymer; and

(b) a fluid suspending medium for said microparticles;

said drug delivery system remaining active in the periodontal pocket for a period of between one and thirty days.

2. The drug delivery system of claim 1, wherein said drug is a prophylactic agent chosen from the group consisting of calcium and fluoride.

3. The drug delivery system of claim 1, wherein said drug is an antiseptic chosen from the group consisting of chlorhexidine and tibezonium iodide.

4. The drug delivery system of claim 1, wherein said drug is an antibiotic.

5. The drug delivery system of claim 4, wherein said antibiotic is chosen from the group consisting of aminoglycosides, macrolides, penicillins and cephalosporins.

6. The drug delivery system of claim 4, wherein said antibiotic is chosen from the group consisting of tetracycline and tetracycline hydrochloride.

7. The drug delivery system of claim 1, wherein said drug is a local anaesthetic.

8. The drug delivery system of claim 7, wherein said local anaesthetic is lidocaine or procaine.

9. The drug delivery system of claim 1, wherein said drug is an anti-inflammatory.

10. The drug delivery system of claim 9, wherein said anti-inflammatory is chosen from the group consisting of ketorolac, naproxen, diclofenac sodium and flurbiprofen.

11. The drug delivery system of claim 1, wherein said drug possesses activity against collagen-destructive enzymes.

12. The drug delivery system of claim 11, wherein said drug is chosen from the group consisting of tetracyclines and sanguinarine, its compounds and derivatives.

13. A method for controlled delivery of a drug to a cavity within the mouth, comprising inserting into said cavity the drug delivery system of claim 1.

14. The method of claim 13, wherein said cavity is a wound.

15. The method of claim 13, wherein said cavity is a socket created by tooth extraction.

16. The method of claim 13, wherein said cavity is a periodontal pocket.

17. The method of claim 13, wherein said cavity is a gingival sulcus.

18. A controlled drug delivery system for placement in a periodontal pocket, comprising:

(a) a plurality of discrete microparticles, between 10 and 500 microns in diameter, comprising a drug and a polymer containing said drug, said drug being essentially insoluble in said polymer, wherein when said microparticles are placed in an environment of use, said drug is released at a controlled rate by erosion of said polymer; and

(b) a fluid suspending medium for said microparticles;

said drug delivery system remaining active in the periodontal pocket for a period of between one and thirty days.

19. The drug delivery system of claim 18, wherein said drug is a prophylactic agent chosen from the group consisting of calcium and fluoride.

20. The drug delivery system of claim 18, wherein said drug is an antiseptic chosen from the group consisting of chlorhexidine and tibezonium iodide.

21. The drug delivery system of claim 18, wherein said drug is an antibiotic.

22. The drug delivery system of claim 21, wherein said antibiotic is chosen from the group consisting of aminoglycosides, macrolides, penicillins and cephalosporins.

23. The drug delivery system of claim 21, wherein said antibiotic is chosen from the group consisting of tetracycline and tetracycline hydrochloride.

24. The drug delivery system of claim 18, wherein said drug is a local anaesthetic.

25. The drug delivery system of claim 24, wherein said local anaesthetic is lidocaine or procaine.

26. The drug delivery system of claim 18, wherein said drug is an anti-inflammatory.

27. The drug delivery system of claim 26, wherein said anti-inflammatory is chosen from the group consisting of ketorolac, naproxen, diclofenac sodium and flurbiprofen.

28. The drug delivery system of claim 18, wherein said drug possesses activity against collagen-destructive enzymes.

29. The drug delivery system of claim 28, wherein said drug is chosen from the group consisting of tetracyclines and sanguinarine, its compounds and derivatives.

30. The drug delivery system of claim 18, wherein said drug is a tissue growth factor.

31. The drug delivery system of claim 30, wherein said tissue growth factor is chosen from the group consisting of epidermal growth factors (EGF), human platelet derived TGF-B, endothelial cell growth factors (ECGF), thymocyte-activating factors (TAF), platelet derived growth factors (PDGF), fibroblast growth factor (FGF), fibronectin and laminin.

32. A method for controlled delivery of a drug to a cavity within the mouth, comprising inserting into said cavity the drug delivery system of claim 18.

33. A controlled drug delivery system for placement in a periodontal pocket, comprising:

(a) a plurality of discrete microparticles, between 10 and 500 microns in diameter, comprising at least 15 vol % drug dispersed in a polymer, said drug being essentially insoluble in said polymer, wherein when said microparticles are placed in an environment of use, said drug is released at a controlled rate by leaching of said drug from said polymer; and

(b) a fluid suspending medium for said microparticles;

said drug delivery system remaining active in the periodontal pocket for a period of between one and thirty days.

34. The drug delivery system of claim 33, wherein said drug is a prophylactic agent chosen from the group consisting of calcium and fluoride.

35. The drug delivery system of claim 33, wherein said drug is an antiseptic chosen from the group consisting of chlorhexidine and tibezonium iodide.

36. The drug delivery system of claim 33, wherein said drug is an antibiotic.

37. The drug delivery system of claim 36, wherein said antibiotic is chosen from the group consisting of aminoglycosides, macrolides, penicillins and cephalosporins.

38. The drug delivery system of claim 36, wherein said antibiotic is chosen from the group consisting of tetracycline and tetracycline hydrochloride.

39. The drug delivery system of claim 33, wherein said drug is a local anaesthetic.

40. The drug delivery system of claim 33, wherein said local anaesthetic is lidocaine or procaine.

41. The drug delivery system of claim 33, wherein said drug is an anti-inflammatory.

42. The drug delivery system of claim 41, wherein said anti-inflammatory is chosen from the group consisting of ketorolac, naproxen, diclofenac sodium and flurbiprofen.

43. The drug delivery system of claim 33, wherein said drug possesses activity against collagen-destructive enzymes.

44. The drug delivery system of claim 43, wherein said drug is chosen from the group consisting of tetracyclines and sanguinarine, its compounds and derivatives.

45. The drug delivery system of claim 33, wherein said drug is a tissue growth factor.

46. The drug delivery system of claim 45, wherein said tissue growth factor is chosen from the group consisting of epidermal growth factors (EGF), human platelet derived TGF-B, endothelial cell growth factors (ECGF), thymocyte-activating factors (TAF), platelet derived growth factors (PDGF), fibroblast growth factor (FGF), fibronectin and laminin.

47. A method for controlled delivery of a drug to a cavity within the mouth, comprising inserting into said cavity the drug delivery system of claim 33.